Mineralys Therapeutics Inc. Common Stock Stock Forecast:
The average target price for Mineralys Therapeutics Inc. Common Stock over the next 12 months, according to 5 analysts, is USD 36.6. Despite this, the average analyst rating for the stock is Strong Buy. Stock Target Advisor’s analysis of the stock is Neutral.
Analysts Coverage Change:
- Stifel Nicolaus initiates coverage on Mineralys Therapeutics Inc. with a “Buy” rating and a target price of $45.
- Credit Suisse initiates coverage with an “Outperform” rating and a target of $40.
- Evercore ISI also initiated coverage with an “Outperform” rating .
- Wells Fargo & Company initiated coverage with an “Overweight” rating and a target price of $27.
- Guggenheim Securities initiated coverage with a “Buy” rating and a target price of $32.
- Bank of America Merrill Lynch initiated coverage with a “Buy” rating and a target price of $39.
About Mineralys Therapeutics Inc.:
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for the treatment of hypertension and associated cardiovascular diseases. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
The primary product candidate of Mineralys Therapeutics is lorundrostat, which is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Aldosterone synthase is an enzyme that plays a key role in the production of aldosterone, a hormone that regulates blood pressure. Lorundrostat inhibits the production of aldosterone, thereby reducing blood pressure and potentially improving cardiovascular outcomes in patients with uncontrolled or resistant hypertension.
FA Score (Fundamental Analysis):
The fundamental analysis of Mineralys Therapeutics Inc is “Neutral” with a FA score of 5 out of 10, where 0 is very bearish and 10 is very bullish.
